sebetralstat
NDA- Indications
- Hereditary angioedema
Company intelligence / Profile preview
DRI Healthcare is a global leader in pharmaceutical royalty monetization. It acquires dependable patent-protected cash flow streams derived from sales of important medicines across multiple therapeutic areas. Since its IPO in 2021 it has deployed over $1 billion acquiring more than 25 royalties on over 20 marketed drugs. Its portfolio focuses on high-impact therapies addressing unmet medical needs and marketed by leading biopharma companies. The firm provides capital to innovators while offering investors exposure to life sciences growth without direct drug development risk.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DRI Healthcare.